[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
Richters A, Aben KKH, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol. 2019.
[3] Palumbo C, Mistretta FA, Knipper S, Pecoraro A, Tian Z, Shariat SF, et al. How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladder. Urol Oncol. 2019;37:893-9.
[4] Zhang N, Wang X, Wang C, Chen S, Wu J, Zhang G, et al. Diagnostic Accuracy of Multi-Parametric Magnetic Resonance Imaging for Tumor Staging of Bladder Cancer: Meta-Analysis. Front Oncol. 2019;9:981.
[5] Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018;74:294-306.
Woo S, Panebianco V, Narumi Y, Del Giudice F, Muglia VF, Takeuchi M, et al. Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2020.
[7] Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017;71:447-61.
[8] Hurle R, Lazzeri M, Vanni E, Lughezzani G, Buffi N, Casale P, et al. Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project. J Urol. 2018;199:401-6.
[9] Schips L, Augustin H, Zigeuner RE, Galle G, Habermann H, Trummer H, et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology. 2002;59:220-3.
[10] McKibben MJ, Woods ME. Preoperative imaging for staging bladder cancer. Curr Urol Rep. 2015;16:22.
[11] Watanabe H, Kanematsu M, Kondo H, Goshima S, Tsuge Y, Onozuka M, et al. Preoperative T staging of urinary bladder cancer: does diffusion-weighted MRI have supplementary value? AJR Am J Roentgenol. 2009;192:1361-6.
[12] Del Giudice F, Barchetti G, De Berardinis E, Pecoraro M, Salvo V, Simone G, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol. 2020;77:101-9.
[13] Barchetti G, Simone G, Ceravolo I, Salvo V, Campa R, Del Giudice F, et al. Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center. Eur Radiol. 2019;29:5498-506.
[14] Thoeny HC, Bellin MF, Comperat EM, Thalmann GN. Vesical Imaging-Reporting and Data System (VI-RADS): Added Value for Management of Bladder Cancer Patients? Eur Urol. 2018;74:307-8.
[15] Makboul M, Farghaly S, Abdelkawi IF. Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application. Br J Radiol. 2019;92:20190401.
Marchioni M, Primiceri G, Delli Pizzi A, Basilico R, Berardinelli F, Mincuzzi E, et al. Could Bladder Multiparametric MRI Be Introduced in Routine Clinical Practice? Role of the New VI-RADS Score: Results From a Prospective Study. Clin Genitourin Cancer. 2020.
Delli Pizzi A, Mastrodicasa D, Marchioni M, Primiceri G, Di Fabio F, Cianci R, et al. Bladder cancer: do we need contrast injection for MRI assessment of muscle invasion? A prospective multi-reader VI-RADS approach. European Radiology. 2020.
[18] Delli Pizzi A, Caposiena D, Mastrodicasa D, Trebeschi S, Lambregts D, Rosa C, et al. Tumor detectability and conspicuity comparison of standard b1000 and ultrahigh b2000 diffusion-weighted imaging in rectal cancer. Abdom Radiol (NY). 2019;44:3595-605.
[19] Fukukura Y, Kumagae Y, Hakamada H, Shindo T, Takumi K, Kamimura K, et al. Computed diffusion-weighted MR imaging for visualization of pancreatic adenocarcinoma: Comparison with acquired diffusion-weighted imaging. European Journal of Radiology. 2017;95:39-45.
Gakis G, Tamada T, Kanomata N, Sone T, Jo Y, Miyaji Y, et al. High b Value (2,000 s/mm2) Diffusion-Weighted Magnetic Resonance Imaging in Prostate Cancer at 3 Tesla: Comparison with 1,000 s/mm2 for Tumor Conspicuity and Discrimination of Aggressiveness. PLoS ONE. 2014;9.
[21] Hausmann D, Liu J, Budjan J, Reichert M, Ong M, Meyer M, et al. Image Quality Assessment of 2D versus 3D T2WI and Evaluation of Ultra-high b-Value (b=2,000 mm/s(2)) DWI for Response Assessment in Rectal Cancer. Anticancer Res. 2018;38:969-78.
[22] Moribata Y, Kido A, Fujimoto K, Himoto Y, Kurata Y, Shitano F, et al. Feasibility of Computed Diffusion Weighted Imaging and Optimization of b-value in Cervical Cancer. Magn Reson Med Sci. 2017;16:66-72.
[23] Ueno Y, Kitajima K, Sugimura K, Kawakami F, Miyake H, Obara M, et al. Ultra-high b-value diffusion-weighted MRI for the detection of prostate cancer with 3-T MRI. J Magn Reson Imaging. 2013;38:154-60.
[24] Haak HE, Maas M, Lahaye MJ, Boellaard TN, Delli Pizzi A, Mihl C, et al. Selection of Patients for Organ Preservation After Chemoradiotherapy: MRI Identifies Poor Responders Who Can Go Straight to Surgery. Ann Surg Oncol. 2020;27:2732-9.
[25] Rosa C, Caravatta L, Delli Pizzi A, Di Tommaso M, Cianci R, Gasparini L, et al. Reproducibility of rectal tumor volume delineation using diffusion-weighted MRI: Agreement on volumes between observers. Cancer Radiother. 2019;23:216-21.
[26] Rosenkrantz AB, Hindman N, Lim RP, Das K, Babb JS, Mussi TC, et al. Diffusion-weighted imaging of the prostate: Comparison of b1000 and b2000 image sets for index lesion detection. J Magn Reson Imaging. 2013;38:694-700.
[27] Necchi A, Bandini M, Calareso G, Raggi D, Pederzoli F, Fare E, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol. 2020;77:636-43.
Necchi A, Messina A, Briganti A. Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018;74:294–306: Validating VI-RADS Criteria Within Immune-oncology Strategies (VI-RADS-IO). Eur Urol. 2018;74:e107-e8.
Del Giudice F, Catto JWF, Panebianco V. Reply to Charalampos Fragkoulis, Georgios Papadopoulos, and Konstantinos Ntoumas's Letter to the Editor re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol 2020;77:101–9. Eur Urol. 2020;77:e94-e5.
[30] Juri H, Narumi Y, Panebianco V, Osuga K. Staging of bladder cancer with multiparametric MRI. Br J Radiol. 2020;93:20200116.
Gmeiner J, Garstka N, Helbich TH, Shariat SF, Baltzer PA. Vesical Imaging Reporting and Data System (VI-RADS): Are the individual MRI sequences equivalent in diagnostic performance of high grade NMIBC and MIBC? Eur J Radiol. 2021;142:109829.
Rabie E, Faeghi F, Izadpanahi MH, Dayani MA. Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Staging of Bladder Cancer. J Clin Diagn Res. 2016;10:TC01–5.
[33] Takeuchi M, Suzuki T, Sasaki S, Ito M, Hamamoto S, Kawai N, et al. Clinicopathologic significance of high signal intensity on diffusion-weighted MR imaging in the ureter, urethra, prostate and bone of patients with bladder cancer. Acad Radiol. 2012;19:827-33.
[34] Wang H, Luo C, Zhang F, Guan J, Li S, Yao H, et al. Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Detrusor Muscle Invasion. Radiology. 2019;291:668-74.
留言 (0)